Novartis Signs an Agreement with Dyno to Develop Novel AVV Therapies Utilizing AI Technology for Ocular Diseases
Novartis’ Zolgensma (onasemnogene abeparvovec) Receives MHLW’s Approval for Spinal Muscular Atrophy
Shots:
- Dyno to receive upfront, research funding, license fees, clinical, regulatory & sales milestones and royalties on WW sales. The company will also utilize its AI technology & its suite of machine learning plus experimental tools for the designing and discovery of novel AAV capsids
- Novartis will be responsible for conducting pre-clinical, clinical trials including the commercialization of gene therapy candidates created via AAV capsids. The focus of the agreement is to utilize Dyno’s CapsidMap AI platform in combination with Novartis’ expertise in gene therapy to develop novel AAV therapies in field of ophthalmology
- CapsidMap platform is enabled with AI technique designed to discover and systematically optimize Adeno-Associated Virus (AAV) capsid vector which will expand and improve the range of diseases treatable with gene therapies
Click here to read full press release/ article | Ref: Buisnesswire | Image: Twitter